Eagle Pharmaceuticals Reports Third Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 31c, Revenues Miss
November 12, 2019 6:53 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.26, $0.31 worse than the analyst estimate of $0.57. Revenue for the quarter came in at $41.15 million versus the consensus estimate of $48.49 million.
Invested $12 million in research and development and external legal costs to advance Eagles pipeline.Eagles Japanese marketing partner, SymBio Pharmaceuticals Limited, submitted a New Drug Application (NDA) for TREAKISYM, bendamustine ready-to-dilute liquid formulation, in Japan in September. Approval is expected in Q4 2020, which would trigger a $5 million milestone payment to Eagle. Potential payments to Eagle could reach $10 to $25 million per year in royalties and... More